Publicacións nas que colabora con Mariano Valdés Chávarri (32)

2019

  1. Impact of anemia as risk factor for major bleeding and mortality in patients with acute coronary syndrome

    European Journal of Internal Medicine, Vol. 61, pp. 48-53

2018

  1. Conservatively managed patients with non-ST-segment elevation acute coronary syndrome are undertreated with indicated medicines

    PLoS ONE, Vol. 13, Núm. 11

  2. Disparities in the estimation of glomerular filtration rate according to cockcroft-gault, modification of diet in renal disease-4, and chronic kidney disease epidemiology collaboration equations and relation with outcomes in patients with acute coronary syndrome

    Journal of the American Heart Association, Vol. 7, Núm. 9

  3. Intra-ventricular thrombus resolution after anticoagulation therapy with rivaroxaban in patient with poor anticoagulation quality

    Cardiology Journal

  4. Temporal Trends in the Use of Antiplatelet Therapy in Patients With Acute Coronary Syndromes

    Journal of Cardiovascular Pharmacology and Therapeutics, Vol. 23, Núm. 1, pp. 57-65

  5. Temporal changes in platelet response in acute coronary syndrome patients with prasugrel and clopidogrel after stent implantation

    Circulation Journal, Vol. 82, Núm. 2, pp. 353-360

2017

  1. Deciphering acute coronary syndrome biomarkers: High-resolution proteomics in platelets, thrombi and microparticles

    Critical Reviews in Clinical Laboratory Sciences, Vol. 54, Núm. 1, pp. 49-58

  2. Efficacy of non-vitamin-K antagonist oral anticoagulants for intracardiac thrombi resolution in nonvalvular atrial fibrillation

    Drug Discovery Today, Vol. 22, Núm. 10, pp. 1565-1571

  3. Low body weight and clinical outcomes in acute coronary syndrome patients: results of the ACHILLES Registry

    European Journal of Cardiovascular Nursing, Vol. 16, Núm. 8, pp. 696-703

  4. Therapeutic management and one-year outcomes in elderly patients with acute coronary syndrome

    Oncotarget, Vol. 8, Núm. 46, pp. 80182-80191

2016

  1. Clinical implications of nonsarcomeric gene polymorphisms in hypertrophic cardiomyopathy

    European Journal of Clinical Investigation, Vol. 46, Núm. 2, pp. 123-129

  2. Platelet reactivity over time in coronary artery disease patients treated with a bioabsorbable everolimus-eluting scaffold

    Platelets, Vol. 27, Núm. 8, pp. 777-783

2015

  1. A comprehensive insight of novel antioxidant therapies for atrial fibrillation management

    Drug Metabolism Reviews, Vol. 47, Núm. 3, pp. 388-400

  2. Biomarkers of necrosis and myocardial remodeling

    General Methods in Biomarker Research and their Applications (Springer International Publishing), pp. 659-688

  3. Comparison of estimated glomerular filtration rate equations for dosing new oral anticoagulants in patients with atrial fibrillation

    Revista Espanola de Cardiologia, Vol. 68, Núm. 6, pp. 497-504

  4. Effects of body mass index on the lipid profile and biomarkers of inflammation and a fibrinolytic and Prothrombotic state

    Journal of Atherosclerosis and Thrombosis, Vol. 22, Núm. 6, pp. 610-617

  5. Involvement of the -420C>G RETN polymorphism in myocardial fibrosis in patients with hypertrophic cardiomyopathy

    Journal of Internal Medicine, Vol. 278, Núm. 1, pp. 50-58

  6. Novel biomarkers in cardiology: MicroRNAs in atrial fibrillation

    Archivos de Cardiologia de Mexico

  7. TWEAK and NT-proBNP levels predict exercise capacity in hypertrophic cardiomyopathy

    European Journal of Clinical Investigation, Vol. 45, Núm. 2, pp. 179-186

2014

  1. High-sensitivity troponin t as a biomarker for the development of atrial fibrillation after cardiac surgery

    European Journal of Cardio-thoracic Surgery, Vol. 45, Núm. 4, pp. 733-738